The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Two doses of NGR-hTNF (N) given alone or in combination with doxorubicin (D) in soft tissue sarcomas (STS).
Stefano Ferrari
No relevant relationships to disclose
Paolo Giovanni Casali
No relevant relationships to disclose
Jean-Yves Blay
Consultant or Advisory Role - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Honoraria - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Expert Testimony - MSD (U)
Giuseppe Tonini
No relevant relationships to disclose
Axel Le Cesne
Honoraria - Novartis; Pfizer; PharmaMar
Nasim Ali
No relevant relationships to disclose
Vittorio Perfetti
No relevant relationships to disclose
Emanuela Palmerini
No relevant relationships to disclose
Elena Palassini
No relevant relationships to disclose
Isabelle Ray-Coquard
No relevant relationships to disclose
Bruno Vincenzi
No relevant relationships to disclose
Julien Domont
No relevant relationships to disclose
Emanuela Marchesi
No relevant relationships to disclose
Andrea Marrari
No relevant relationships to disclose
Philippe Alexandre Cassier
No relevant relationships to disclose
Marianna Silletta
No relevant relationships to disclose
Silvia Stacchiotti
No relevant relationships to disclose
Antonio Lambiase
Employment or Leadership Position - MolMed
Claudio Bordignon
Employment or Leadership Position - MolMed